Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Asian Pac J Cancer Prev ; 15(15): 6087-94, 2014.
Article in English | MEDLINE | ID: mdl-25124578

ABSTRACT

PURPOSE: The aim of the present study was to invesitigate the impact of significant clinico-pathological prognostic factors on survival rates and to identify factors predictive of poor outcome in patients with ovarian carcinoma. MATERIALS AND METHODS: A retrospective chart review of 74 women with pathologically proven ovarian carcinoma who were treated between January 2006 and April 2011 was performed. Patients were investigated with respect to survival to find the possible effects of age, gravida, parity, menstruel condition, pre-operative Ca-125, treatment period, cytologic washings, presence of ascites, tumor histology, stage and grade, maximal tumor diameter, adjuvan chemotherapy and cytoreductive success. Also 55 ovarian carcinoma patients were investigated with respect to prognostic factors for early 2-year survival. RESULTS: The two-year survival rate was 69% and the 5-year survival rate was 25.5% for the whole study population. Significant factors for 2-year survival were preoperative CA-125 level, malignant cytology and FIGO clinical stage. Significant factors for 5-year survival were age, preoperative CA-125 level, residual tumor, lymph node metastases, histologic type of tumor, malignant cytology and FIGO clinical stage. Logistic regression revealed that independent prognostic factors of 5-year survival were patient age, lymph node metastasis and malignant cytology. CONCLUSIONS: We consider quality registries with prospectively collected data to be one important tool in monitoring treatment effects in population-based cancer research.


Subject(s)
Adenocarcinoma, Clear Cell/mortality , Adenocarcinoma, Mucinous/mortality , Cystadenocarcinoma, Serous/mortality , Endometrial Neoplasms/mortality , Neoplasm, Residual/mortality , Ovarian Neoplasms/mortality , Adenocarcinoma, Clear Cell/secondary , Adenocarcinoma, Clear Cell/therapy , Adenocarcinoma, Mucinous/secondary , Adenocarcinoma, Mucinous/therapy , Adult , Aged , Aged, 80 and over , Combined Modality Therapy , Cystadenocarcinoma, Serous/secondary , Cystadenocarcinoma, Serous/therapy , Endometrial Neoplasms/secondary , Endometrial Neoplasms/therapy , Female , Follow-Up Studies , Humans , Lymphatic Metastasis , Middle Aged , Neoplasm Grading , Neoplasm Staging , Neoplasm, Residual/pathology , Neoplasm, Residual/therapy , Ovarian Neoplasms/pathology , Ovarian Neoplasms/therapy , Prognosis , Retrospective Studies , Survival Rate
SELECTION OF CITATIONS
SEARCH DETAIL
...